PMI Didn't Buy Swedish Match to Diversify. It Bought a Door Back into America.

In Q1 2024, more than 74 cents of every dollar Americans spent on nicotine pouches went to a single product made by a company headquartered in Stockholm and now owned by one in Switzerland.⁹ The product is ZYN — a small white pouch you tuck under your lip, no smoke, no spit. PMI shipped 384.8 million cans of it in the US in 2023 and 581.4 million in 2024, the latter generating $1.88 billion in net revenue.⁹ To buy that machine, Philip Morris International spent roughly $16 billion.⁴ The headlines called it a bet on the future of nicotine. It was really something less glamorous and far more revealing: a company buying its way back into a country it had given up the right to sell in.

The official story is that PMI diversified into smoke-free products by acquiring Swedish Match in 2022. Strike most of that. PMI didn't diversify — it had no choice. And it didn't acquire Swedish Match in 2022 so much as begin a slow siege that wouldn't end until 2023.³ To understand why a cigarette giant paid a premium for a Swedish snus maker, you have to start with a map of the United States — and the fact that PMI wasn't allowed to be on it.

The company that sold the world but not its home

When PMI spun off from Altria in 2008, the divorce came with a wall down the middle of the map: Altria kept the United States, PMI kept everywhere else. That arrangement was fine while the business was cigarettes — but PMI had staked its entire future on going smoke-free, and the largest, richest nicotine market on earth was the one address it could not reach. It had tried the partnership route once already. From February 2009 to 2015, PMI and Swedish Match ran a 50/50 joint venture, SMPM International, to push snus into markets like Tel Aviv, St. Petersburg, Taiwan, and Canada. It failed for the most ordinary reason a product fails: nobody wanted it. The JV was dissolved in 2015.⁵ So the popular line that PMI and Swedish Match were strangers before the deal is exactly backwards. They were ex-partners who had already tried to build the smaller version of this and watched it collapse.

Here is the thesis, plainly: PMI's Swedish Match deal was not a portfolio bet — it was a structurally necessary re-entry into the United States, and ZYN was the only ticket that worked. Building a US nicotine-pouch business from scratch would have meant years of trial against an incumbent that had already won. Swedish Match had spent that time and survived it. ZYN was first marketed not in 2014 — that was the Sweden launch — but in Colorado and the western US in 2016.⁶ By 2018 the US snus and pouch segment turned its first profit, on just 12.7 million cans; 2019 jumped to 50.4 million.⁶ PMI wasn't buying a promising startup. It was buying a category that had already crossed the chasm — and a national distribution network it would otherwise have had to assemble pouch by pouch, store by store.

The siege that cost an extra SEK 10 a share

The deal that gets summarized as 'PMI acquired Swedish Match in 2022' was actually a grinding, contested takeover that resisted tidy closure. PMI's Dutch subsidiary, Philip Morris Holland Holdings, launched an all-cash tender offer on May 11, 2022 at SEK 106 per share.¹ Then it ran into a wall named Elliott Management, the activist fund, which had built a stake of roughly 10.5% and used it to block the cheap exit.¹⁰ Sweden's takeover law sets a 90% threshold for squeezing out remaining holders — and a single fund holding more than 10% can hold that gate shut. PMI was forced to raise its best-and-final price to SEK 116, an increase of SEK 10 a share, about 9.4% more than where it started.¹ Only then, on November 7, 2022, did PMHH declare the offer unconditional, having reached 82.59% — still short of the 90% it needed.² It kept buying. By late November it held 93.11% and could finally start compulsory redemption.³ Full ownership didn't complete until 2023.³

That extra SEK 10 matters because it tells you what PMI thought it was buying. You do not pay a forced 9.4% premium, against an activist who has read your weakness perfectly, for an asset you could replicate. PMI paid the ransom because there was no second ZYN to bid on. The scarcity was the point — and Elliott knew it.¹⁰

The valuation only works if the regulators stay friendly

A 74% share is a glorious thing right up until the rules change. And ZYN's position rests on two regulatory pillars that are weaker than the market price assumes. In January 2025 the FDA authorized 20 ZYN products through the PMTA pathway — the first-ever clearance for oral nicotine pouches in the US, across two strengths and ten flavors.⁷ That sounds like victory, and it is a real one. But a PMTA authorization is permission to sell, nothing more. It explicitly does not let PMI tell anyone ZYN is safer than cigarettes.⁷ The claim that would actually move smokers — a reduced-risk designation — runs through a separate, far harder door called MRTP. Swedish Match USA's MRTP application only entered substantive FDA scientific review on June 17, 2025, and no order had been granted as of mid-2025.⁸ So the single most valuable marketing message PMI could attach to ZYN remains, for now, illegal to say.

Isn't 74% a moat in itself?

The fair objection is that this analysis underrates ZYN. A product with more than 74% of a fast-growing category, first-mover FDA clearance, and US volumes that doubled in two years isn't a fragile bet — it's a category-defining one, and PMI bought it before it became obvious. That's a strong case, and the volume curve supports it: 237 million cans in 2022, 384.8 million in 2023, 581.4 million in 2024.⁹ But notice what the steelman quietly assumes — that the dominance is durable. The whole valuation premium, including the SEK 10 PMI was forced to add, rests on ZYN holding that share against two pressures it has not yet faced at scale: competitors now that the FDA has shown a pouch can be authorized, and a regulatory regime that can grant or withhold the reduced-risk claim that would widen the market. A near-monopoly built in a regulatory vacuum is worth a great deal less the moment the vacuum fills. PMI didn't buy a finished moat. It bought a commanding lead in a race that just got an official starting gun.

PMI's old vision of going 'predominantly smoke-free by 2025' has already quietly slipped — reframed in later communications as smoke-free revenue reaching the mid-sixties percent by 2030. The Swedish Match deal is what that slippage looks like in cash: when the clock runs ahead of your organic progress, you buy the years back. PMI gave up the United States in 2008 and spent $16 billion in 2022 to undo the decision, on terms set partly by an activist who saw it couldn't walk away.¹⁰⁴ The pouch under the lip is the smallest object in this story. The biggest is the door PMI closed on itself fourteen years earlier — and the price of finding the only key that still fit.